Initiative, which was launched just eight months ago in July 2007.
First-round funding includes support for organizations working in Cameroon,
Côte d'Ivoire, Curacao, Ghana, Haiti, Jamaica, Malaysia, Mali, Mauritius,
Myanmar, Nigeria, Thailand and Zimbabwe. The MSM Initiative received more
than 120 applications from organizations in developing countries, with more
than 85 from Africa alone, far exceeding expectations.
"The response to our first request for proposals (RFP) for funding the
MSM Initiative has been overwhelming, demonstrating the enormous unmet
need, particularly in parts of the world where vulnerable populations have
few established support systems," Frost said. "Through the MSM Initiative,
we hope to foster collaboration among organizations, promote advocacy that
transforms attitudes and discriminatory policies, and increase HIV/AIDS
funding worldwide for MSM."
A second RFP will be issued on February 22. It will target groups
working in Central and South America and Asia and the Pacific.
"For too long, countries around the world have simply assumed MSM do
not exist, leaving millions underserved and vulnerable to HIV infection,"
said Stella Iwuagwu, Executive Director at the Center for the Right to
Health in Abuja, Nigeria. "The MSM Initiative provides important resources
to help us expand our work to empower MSM in Nigeria and ensure that
education, condoms, and treatment are available to all."
Data on HIV rates among MSM in developing countries are sparse but a
recent study by researchers at Johns Hopkins University produced some
startling findings. Published in the online journal PLoS Medicine, their
research showed that in 38 low- and middle-income countries, MSM have an
average 19 times greater chance of being infected with HIV than the general
population. In some countries MSM are more than 100 times more likely to be
infected, the study found.
The MSM Initiative is facilitated by amfAR, with va
Page: 1 2 3 Related medicine technology :1
|SOURCE amfAR, The Foundation for AIDS Research|
Copyright©2008 PR Newswire.
All rights reserved
. ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line2
. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)3
. Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial4
. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial5
. On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments6
. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections7
. Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin8
. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients9
. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds10
. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas11
. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia